Elsevier

The Lancet

Volume 352, Issue 9129, 29 August 1998, Pages 726-729
The Lancet

Public Health
Intellectual property, drug licensing, freedom of information, and public health

https://doi.org/10.1016/S0140-6736(98)07600-4Get rights and content

First page preview

First page preview
Click to open first page preview

References (19)

  • E Ollila E. Hemminki

    Secrecy of drug regulation

    Int J Risk Safety Med

    (1996)
  • T Dent et al.

    Too soon to market

    BMJ

    (1997)
  • BoseleyS

    Hard to swallow

    Guardian

    (23 April 1998)
  • M Montagne

    The role of clinical research in the drug development process

  • E Hemminki

    Study information submitted by drug companies to licensing authorities

    BMJ

    (1980)
  • T Peters

    All about albumin: biochemistry, genetics and medical applications

    (1996)
  • ABPI compendium of data sheets and summaries of product characteristics 1998–99

    (1998)
  • P Mitchell

    Review sparks controversy over human albumin therapy

    Lancet

    (1998)
  • Albumin administration in critically ill patients (Cochrane Review)

    The Cochrane Library

    (1998)
There are more references available in the full text version of this article.

Cited by (18)

  • Development of Marketing Authorisation Procedures for Pharmaceuticals

    2007, Evaluating Pharmaceuticals for Health Policy and Reimbursement
View all citing articles on Scopus
View full text